Researchers at Johns Hopkins Bloomberg School of Public Health have discovered a genetic mutation in the FluMist intranasal flu vaccine that has the potential to be altered to enhance the vaccine’s protective effect.
This flu season marks the second that the panel that advises the Centers for Disease Control and Prevention (CDC) on vaccines has recommended that FluMist not be used in the U.S. The Advisory Committee on Immunization Practice found that the vaccine had grown less effective in recent years, possibly due to shifts in circulating flu strains, and researchers have been searching for ways to restore its effectiveness.
In the new study, the Bloomberg School researchers discovered a previously overlooked mutation, present within two of the viral strains used in the vaccine, that reduces virus production. When the researchers reversed the mutation in one of the viruses, the virus became more active, making copies of itself – which is known as replicating – more quickly in cultured human nasal cells and inducing a stronger production of immune proteins.
The findings appear in the journal Vaccine.
“Only one component of FluMist – the one targeting the Type A H1N1 virus – has been failing in the U.S. recently,” says Andrew S. Pekosz, PhD, professor in the Bloomberg School’s Department of Molecular Microbiology and Immunology. “It’s not clear exactly why it has failed but this mutation we identified could be used to make that component of the vaccine a little stronger, thereby improving vaccine efficacy. We now see the possibility of altering this mutation and perhaps others in the vaccine to optimize the vaccine’s protective effect, perhaps for different age groups.”
Three types of influenza viruses affect people, Type A, Type B and Type C, and flu vaccines include a mix of virus strains tailored to anticipate the upcoming flu season. The CDC estimates that over the past seven years, flu viruses have caused 9.2 million to 60.8 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually in the U.S. Across the globe, there are an estimated three to five million cases of severe flu cases and about 250,000 to 500,000 deaths.
The FluMist vaccine, also known as LAIV (live, attenuated influenza vaccine) is made from four weakened flu virus strains, two representing the influenza A type, and two representing the influenza B type. Two segments of the strains used in the vaccine are altered periodically to match the strains of influenza circulating in the population.
The non-varying parts of the vaccine are made from a special, cold-adapted H2N2 strain that is known to contain mutations that slow its replication at the temperatures found in the human nose and throat. That slowing of activity is largely what keeps these vaccine strains from causing illness in people, although they remain active enough to induce at least partial immune protection against future influenza A infections.
Scientists in previous studies have linked the slower replication of this cold-adapted strain to changes in three virus genes. However, there have been hints in recent years, from Pekosz’s work and others’, that another gene encoding a viral protein called M2 may also contribute to this effect.
“We had studied M2 for years, but one day recently a student in my lab noticed that the M2 in the LAIV influenza A viruses contains a mutation in the same part of the protein that we had previously identified as affecting viral replication,” Pekosz says.
The researchers found that when they introduced this same mutation into a strain of influenza A virus that normally doesn’t have it, the replication rate of the virus dropped. Alternate mutations at the same site on the M2 gene also resulted in a slowing of viral replication.
The team then did the opposite experiment, starting with a FluMist influenza A strain and reversing the M2 mutation. They found that this enhanced the replication rate of the strain in human nasal cells.
The enhanced activity of the virus also led to a jump in production, in infected cells, of the immune protein interferon lambda, indicating an increased immune response. The result showed in principle that this mutation site, and perhaps others on the virus, may be used as “dimmer switches” to adjust the vaccine’s strength up or down—so that it induces a robustly protective immune response without also causing illness.
“What we’re trying to do now is make a panel of these LAIV viruses with different mutations to see if we can boost the replication rates to get vaccine formulations that protect children and other age groups better than LAIV has done in the past few years,” Pekosz says.
“The M2 protein of live, attenuated influenza vaccine encodes a mutation that reduces replication in human nasal epithelial cells” was written by Nicholas Wohlgemuth, Yang Ye, Katherine J. Fenstermacher, Hsuan Liu, Andrew P. Lane, and Andrew Pekosz.
Support for the research was provided by the U.S. National Institutes of Health (R01 AI097417, HHSN272201400007C, R01 AI072502 and T32 AI007417) and the Shikani/El Hibri Prize for Discovery and Innovation.
Source: Johns Hopkins Bloomberg School of Public Health